nodes	percent_of_prediction	percent_of_DWPC	metapath
Zalcitabine—CYP3A43—Dexamethasone—psoriasis	0.108	0.166	CbGbCtD
Zalcitabine—CYP3A5—Beclomethasone—psoriasis	0.0595	0.0912	CbGbCtD
Zalcitabine—SLC22A7—Methotrexate—psoriasis	0.0326	0.05	CbGbCtD
Zalcitabine—CYP2D6—Hydroxyurea—psoriasis	0.0276	0.0424	CbGbCtD
Zalcitabine—SLC22A6—Cyclosporine—psoriasis	0.0262	0.0402	CbGbCtD
Zalcitabine—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0253	0.0389	CbGbCtD
Zalcitabine—CYP3A7—Hydrocortisone—psoriasis	0.0253	0.0389	CbGbCtD
Zalcitabine—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0239	0.0367	CbGbCtD
Zalcitabine—CYP3A7—Cyclosporine—psoriasis	0.0239	0.0367	CbGbCtD
Zalcitabine—CYP3A5—Mycophenolate mofetil—psoriasis	0.0237	0.0363	CbGbCtD
Zalcitabine—CYP3A4—Calcitriol—psoriasis	0.0207	0.0317	CbGbCtD
Zalcitabine—CYP3A5—Hydrocortisone—psoriasis	0.019	0.0291	CbGbCtD
Zalcitabine—CYP2C9—Cholecalciferol—psoriasis	0.0183	0.0281	CbGbCtD
Zalcitabine—CYP3A5—Cyclosporine—psoriasis	0.0179	0.0275	CbGbCtD
Zalcitabine—CYP2D6—Cholecalciferol—psoriasis	0.0167	0.0257	CbGbCtD
Zalcitabine—CYP3A4—Methoxsalen—psoriasis	0.0161	0.0247	CbGbCtD
Zalcitabine—CYP3A7—Dexamethasone—psoriasis	0.0158	0.0242	CbGbCtD
Zalcitabine—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.0158	0.0242	CbGbCtD
Zalcitabine—SLC22A6—Methotrexate—psoriasis	0.0139	0.0213	CbGbCtD
Zalcitabine—CYP2C9—Cyclosporine—psoriasis	0.012	0.0185	CbGbCtD
Zalcitabine—CYP3A5—Dexamethasone—psoriasis	0.0118	0.0181	CbGbCtD
Zalcitabine—CYP2D6—Cyclosporine—psoriasis	0.011	0.0169	CbGbCtD
Zalcitabine—CYP3A4—Cholecalciferol—psoriasis	0.0106	0.0163	CbGbCtD
Zalcitabine—CYP3A4—Mycophenolate mofetil—psoriasis	0.00923	0.0142	CbGbCtD
Zalcitabine—CYP3A4—Triamcinolone—psoriasis	0.00923	0.0142	CbGbCtD
Zalcitabine—CYP2C9—Dexamethasone—psoriasis	0.00792	0.0122	CbGbCtD
Zalcitabine—CYP3A4—Betamethasone—psoriasis	0.00792	0.0122	CbGbCtD
Zalcitabine—CYP3A4—Prednisolone—psoriasis	0.00782	0.012	CbGbCtD
Zalcitabine—CYP3A4—Hydrocortisone—psoriasis	0.00741	0.0114	CbGbCtD
Zalcitabine—CYP3A4—Prednisone—psoriasis	0.00738	0.0113	CbGbCtD
Zalcitabine—CYP2D6—Dexamethasone—psoriasis	0.00725	0.0111	CbGbCtD
Zalcitabine—CYP3A4—Cyclosporine—psoriasis	0.007	0.0107	CbGbCtD
Zalcitabine—CYP3A43—Miscellaneous substrates—CYP2S1—psoriasis	0.00598	0.151	CbGpPWpGaD
Zalcitabine—CYP3A4—Dexamethasone—psoriasis	0.00461	0.00707	CbGbCtD
Zalcitabine—CYP3A43—Xenobiotics—CYP2S1—psoriasis	0.00397	0.1	CbGpPWpGaD
Zalcitabine—CYP3A43—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00165	0.0417	CbGpPWpGaD
Zalcitabine—CYP3A43—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00163	0.0412	CbGpPWpGaD
Zalcitabine—CYP3A7—Xenobiotics—CYP2S1—psoriasis	0.0016	0.0405	CbGpPWpGaD
Zalcitabine—CYP3A43—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00134	0.0338	CbGpPWpGaD
Zalcitabine—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00133	0.0335	CbGpPWpGaD
Zalcitabine—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00132	0.0333	CbGpPWpGaD
Zalcitabine—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00124	0.0313	CbGpPWpGaD
Zalcitabine—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.00116	0.0292	CbGpPWpGaD
Zalcitabine—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000823	0.0208	CbGpPWpGaD
Zalcitabine—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000816	0.0206	CbGpPWpGaD
Zalcitabine—DCK—Purine metabolism—CAT—psoriasis	0.000812	0.0205	CbGpPWpGaD
Zalcitabine—CYP3A43—Biological oxidations—CYP2S1—psoriasis	0.000711	0.018	CbGpPWpGaD
Zalcitabine—CYP3A43—Metapathway biotransformation—CYP2S1—psoriasis	0.000701	0.0177	CbGpPWpGaD
Zalcitabine—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000665	0.0168	CbGpPWpGaD
Zalcitabine—CYP3A7—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000656	0.0166	CbGpPWpGaD
Zalcitabine—CYP3A7—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000539	0.0136	CbGpPWpGaD
Zalcitabine—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000538	0.0136	CbGpPWpGaD
Zalcitabine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00048	0.0121	CbGpPWpGaD
Zalcitabine—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000474	0.012	CbGpPWpGaD
Zalcitabine—SLC29A2—SLC-mediated transmembrane transport—CP—psoriasis	0.000455	0.0115	CbGpPWpGaD
Zalcitabine—DCK—Desoximetasone—Clobetasol propionate—psoriasis	0.00044	0.0931	CbGdCrCtD
Zalcitabine—DCK—Diflorasone—Clobetasol propionate—psoriasis	0.000427	0.0903	CbGdCrCtD
Zalcitabine—DCK—Nucleotide metabolism—CAT—psoriasis	0.000408	0.0103	CbGpPWpGaD
Zalcitabine—SLC22A7—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000396	0.01	CbGpPWpGaD
Zalcitabine—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000389	0.00984	CbGpPWpGaD
Zalcitabine—DCK—Desoximetasone—Beclomethasone—psoriasis	0.000352	0.0745	CbGdCrCtD
Zalcitabine—DCK—Desoximetasone—Fluocinonide—psoriasis	0.000352	0.0745	CbGdCrCtD
Zalcitabine—DCK—Desoximetasone—Fluocinolone Acetonide—psoriasis	0.000342	0.0724	CbGdCrCtD
Zalcitabine—DCK—Diflorasone—Beclomethasone—psoriasis	0.000342	0.0723	CbGdCrCtD
Zalcitabine—DCK—Diflorasone—Fluocinonide—psoriasis	0.000342	0.0723	CbGdCrCtD
Zalcitabine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000342	0.00863	CbGpPWpGaD
Zalcitabine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000339	0.00856	CbGpPWpGaD
Zalcitabine—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000337	0.00852	CbGpPWpGaD
Zalcitabine—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000334	0.00845	CbGpPWpGaD
Zalcitabine—DCK—Diflorasone—Fluocinolone Acetonide—psoriasis	0.000332	0.0703	CbGdCrCtD
Zalcitabine—DCK—Retinoblastoma (RB) in Cancer—PCNA—psoriasis	0.000322	0.00814	CbGpPWpGaD
Zalcitabine—SLC29A1—SLC-mediated transmembrane transport—CP—psoriasis	0.000315	0.00797	CbGpPWpGaD
Zalcitabine—SLC29A1—Fluoropyrimidine Activity—TP53—psoriasis	0.000306	0.00773	CbGpPWpGaD
Zalcitabine—CYP3A7—Biological oxidations—CYP2S1—psoriasis	0.000286	0.00723	CbGpPWpGaD
Zalcitabine—CYP3A7—Metapathway biotransformation—CYP2S1—psoriasis	0.000282	0.00713	CbGpPWpGaD
Zalcitabine—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000277	0.00701	CbGpPWpGaD
Zalcitabine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000277	0.007	CbGpPWpGaD
Zalcitabine—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000275	0.00694	CbGpPWpGaD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—CP—psoriasis	0.000231	0.00584	CbGpPWpGaD
Zalcitabine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000223	0.00565	CbGpPWpGaD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—CARM1—psoriasis	0.000221	0.00558	CbGpPWpGaD
Zalcitabine—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00022	0.00557	CbGpPWpGaD
Zalcitabine—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.000207	0.00523	CbGpPWpGaD
Zalcitabine—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.000204	0.00516	CbGpPWpGaD
Zalcitabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000181	0.00458	CbGpPWpGaD
Zalcitabine—SLC22A7—SLC-mediated transmembrane transport—CP—psoriasis	0.00018	0.00454	CbGpPWpGaD
Zalcitabine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000179	0.00451	CbGpPWpGaD
Zalcitabine—SLC22A7—Fluoropyrimidine Activity—TP53—psoriasis	0.000174	0.0044	CbGpPWpGaD
Zalcitabine—DCK—Desoximetasone—Hydrocortisone—psoriasis	0.000173	0.0366	CbGdCrCtD
Zalcitabine—DCK—Desoximetasone—Dexamethasone—psoriasis	0.00016	0.034	CbGdCrCtD
Zalcitabine—DCK—Desoximetasone—Betamethasone—psoriasis	0.00016	0.034	CbGdCrCtD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—CP—psoriasis	0.00016	0.00405	CbGpPWpGaD
Zalcitabine—DCK—Desoximetasone—Triamcinolone—psoriasis	0.000157	0.0332	CbGdCrCtD
Zalcitabine—DCK—Diflorasone—Dexamethasone—psoriasis	0.000156	0.033	CbGdCrCtD
Zalcitabine—DCK—Diflorasone—Betamethasone—psoriasis	0.000156	0.033	CbGdCrCtD
Zalcitabine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000156	0.00393	CbGpPWpGaD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—CARM1—psoriasis	0.000153	0.00386	CbGpPWpGaD
Zalcitabine—DCK—Diflorasone—Triamcinolone—psoriasis	0.000152	0.0322	CbGdCrCtD
Zalcitabine—DCK—Desoximetasone—Prednisone—psoriasis	0.000149	0.0315	CbGdCrCtD
Zalcitabine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000147	0.00372	CbGpPWpGaD
Zalcitabine—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000146	0.00369	CbGpPWpGaD
Zalcitabine—DCK—Desoximetasone—Prednisolone—psoriasis	0.000145	0.0307	CbGdCrCtD
Zalcitabine—DCK—Metabolism—NDUFA5—psoriasis	0.000145	0.00367	CbGpPWpGaD
Zalcitabine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000145	0.00367	CbGpPWpGaD
Zalcitabine—DCK—Diflorasone—Prednisone—psoriasis	0.000144	0.0306	CbGdCrCtD
Zalcitabine—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000144	0.00364	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—NDUFA5—psoriasis	0.000143	0.00361	CbGpPWpGaD
Zalcitabine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000143	0.00361	CbGpPWpGaD
Zalcitabine—DCK—Diflorasone—Prednisolone—psoriasis	0.000141	0.0298	CbGdCrCtD
Zalcitabine—SLC22A6—SLC-mediated transmembrane transport—CP—psoriasis	0.000126	0.00319	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—CYP2S1—psoriasis	0.000123	0.00312	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—CYP2S1—psoriasis	0.000122	0.00307	CbGpPWpGaD
Zalcitabine—DCK—Retinoblastoma (RB) in Cancer—TP53—psoriasis	0.000118	0.00299	CbGpPWpGaD
Zalcitabine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000108	0.00274	CbGpPWpGaD
Zalcitabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000103	0.00259	CbGpPWpGaD
Zalcitabine—DCK—Levonorgestrel—Hydrocortisone—psoriasis	0.000101	0.0214	CbGdCrCtD
Zalcitabine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	9.62e-05	0.00243	CbGpPWpGaD
Zalcitabine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	9.49e-05	0.0024	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—CP—psoriasis	9.13e-05	0.00231	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—CARM1—psoriasis	8.71e-05	0.0022	CbGpPWpGaD
Zalcitabine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	8.48e-05	0.00214	CbGpPWpGaD
Zalcitabine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	8.3e-05	0.0021	CbGpPWpGaD
Zalcitabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.15e-05	0.00181	CbGpPWpGaD
Zalcitabine—Dry mouth—Triamcinolone—psoriasis	7.09e-05	0.000233	CcSEcCtD
Zalcitabine—Decreased appetite—Mycophenolate mofetil—psoriasis	7.04e-05	0.000232	CcSEcCtD
Zalcitabine—Anorexia—Hydrocortisone—psoriasis	7.03e-05	0.000232	CcSEcCtD
Zalcitabine—Diarrhoea—Mycophenolic acid—psoriasis	7.02e-05	0.000231	CcSEcCtD
Zalcitabine—Malaise—Dexamethasone—psoriasis	6.97e-05	0.000229	CcSEcCtD
Zalcitabine—Malaise—Betamethasone—psoriasis	6.97e-05	0.000229	CcSEcCtD
Zalcitabine—Oedema—Triamcinolone—psoriasis	6.95e-05	0.000229	CcSEcCtD
Zalcitabine—Vertigo—Betamethasone—psoriasis	6.94e-05	0.000228	CcSEcCtD
Zalcitabine—Vertigo—Dexamethasone—psoriasis	6.94e-05	0.000228	CcSEcCtD
Zalcitabine—Syncope—Betamethasone—psoriasis	6.93e-05	0.000228	CcSEcCtD
Zalcitabine—Syncope—Dexamethasone—psoriasis	6.93e-05	0.000228	CcSEcCtD
Zalcitabine—Pain—Mycophenolate mofetil—psoriasis	6.93e-05	0.000228	CcSEcCtD
Zalcitabine—Arrhythmia—Prednisone—psoriasis	6.9e-05	0.000227	CcSEcCtD
Zalcitabine—Infection—Triamcinolone—psoriasis	6.9e-05	0.000227	CcSEcCtD
Zalcitabine—Feeling abnormal—Cyclosporine—psoriasis	6.84e-05	0.000225	CcSEcCtD
Zalcitabine—Shock—Triamcinolone—psoriasis	6.84e-05	0.000225	CcSEcCtD
Zalcitabine—Insomnia—Prednisolone—psoriasis	6.83e-05	0.000225	CcSEcCtD
Zalcitabine—Alopecia—Prednisone—psoriasis	6.83e-05	0.000225	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Cyclosporine—psoriasis	6.79e-05	0.000224	CcSEcCtD
Zalcitabine—Loss of consciousness—Dexamethasone—psoriasis	6.79e-05	0.000224	CcSEcCtD
Zalcitabine—Loss of consciousness—Betamethasone—psoriasis	6.79e-05	0.000224	CcSEcCtD
Zalcitabine—Dizziness—Mycophenolic acid—psoriasis	6.79e-05	0.000223	CcSEcCtD
Zalcitabine—Epistaxis—Methotrexate—psoriasis	6.79e-05	0.000223	CcSEcCtD
Zalcitabine—Tachycardia—Triamcinolone—psoriasis	6.78e-05	0.000223	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Hydrocortisone—psoriasis	6.72e-05	0.000221	CcSEcCtD
Zalcitabine—Hyperhidrosis—Triamcinolone—psoriasis	6.72e-05	0.000221	CcSEcCtD
Zalcitabine—Convulsion—Betamethasone—psoriasis	6.69e-05	0.00022	CcSEcCtD
Zalcitabine—Convulsion—Dexamethasone—psoriasis	6.69e-05	0.00022	CcSEcCtD
Zalcitabine—Feeling abnormal—Mycophenolate mofetil—psoriasis	6.68e-05	0.00022	CcSEcCtD
Zalcitabine—Insomnia—Hydrocortisone—psoriasis	6.68e-05	0.00022	CcSEcCtD
Zalcitabine—Hypertension—Betamethasone—psoriasis	6.67e-05	0.00022	CcSEcCtD
Zalcitabine—Hypertension—Dexamethasone—psoriasis	6.67e-05	0.00022	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	6.62e-05	0.000218	CcSEcCtD
Zalcitabine—Urticaria—Cyclosporine—psoriasis	6.6e-05	0.000217	CcSEcCtD
Zalcitabine—Myalgia—Dexamethasone—psoriasis	6.58e-05	0.000217	CcSEcCtD
Zalcitabine—Myalgia—Betamethasone—psoriasis	6.58e-05	0.000217	CcSEcCtD
Zalcitabine—Abdominal pain—Cyclosporine—psoriasis	6.56e-05	0.000216	CcSEcCtD
Zalcitabine—Body temperature increased—Cyclosporine—psoriasis	6.56e-05	0.000216	CcSEcCtD
Zalcitabine—Anxiety—Dexamethasone—psoriasis	6.55e-05	0.000216	CcSEcCtD
Zalcitabine—Anxiety—Betamethasone—psoriasis	6.55e-05	0.000216	CcSEcCtD
Zalcitabine—Vomiting—Mycophenolic acid—psoriasis	6.53e-05	0.000215	CcSEcCtD
Zalcitabine—Discomfort—Dexamethasone—psoriasis	6.5e-05	0.000214	CcSEcCtD
Zalcitabine—Discomfort—Betamethasone—psoriasis	6.5e-05	0.000214	CcSEcCtD
Zalcitabine—Dyspepsia—Hydrocortisone—psoriasis	6.5e-05	0.000214	CcSEcCtD
Zalcitabine—Rash—Mycophenolic acid—psoriasis	6.47e-05	0.000213	CcSEcCtD
Zalcitabine—Dermatitis—Mycophenolic acid—psoriasis	6.47e-05	0.000213	CcSEcCtD
Zalcitabine—Pain—Prednisolone—psoriasis	6.46e-05	0.000213	CcSEcCtD
Zalcitabine—Hepatitis—Methotrexate—psoriasis	6.46e-05	0.000213	CcSEcCtD
Zalcitabine—Urticaria—Mycophenolate mofetil—psoriasis	6.44e-05	0.000212	CcSEcCtD
Zalcitabine—Headache—Mycophenolic acid—psoriasis	6.43e-05	0.000212	CcSEcCtD
Zalcitabine—Decreased appetite—Hydrocortisone—psoriasis	6.42e-05	0.000211	CcSEcCtD
Zalcitabine—Pharyngitis—Methotrexate—psoriasis	6.41e-05	0.000211	CcSEcCtD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—CP—psoriasis	6.41e-05	0.00162	CbGpPWpGaD
Zalcitabine—Body temperature increased—Mycophenolate mofetil—psoriasis	6.4e-05	0.000211	CcSEcCtD
Zalcitabine—Abdominal pain—Mycophenolate mofetil—psoriasis	6.4e-05	0.000211	CcSEcCtD
Zalcitabine—Fatigue—Hydrocortisone—psoriasis	6.36e-05	0.000209	CcSEcCtD
Zalcitabine—Vision blurred—Prednisone—psoriasis	6.34e-05	0.000209	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Triamcinolone—psoriasis	6.33e-05	0.000208	CcSEcCtD
Zalcitabine—Pain—Hydrocortisone—psoriasis	6.31e-05	0.000208	CcSEcCtD
Zalcitabine—Oedema—Betamethasone—psoriasis	6.31e-05	0.000208	CcSEcCtD
Zalcitabine—Oedema—Dexamethasone—psoriasis	6.31e-05	0.000208	CcSEcCtD
Zalcitabine—Insomnia—Triamcinolone—psoriasis	6.29e-05	0.000207	CcSEcCtD
Zalcitabine—Infection—Dexamethasone—psoriasis	6.26e-05	0.000206	CcSEcCtD
Zalcitabine—Infection—Betamethasone—psoriasis	6.26e-05	0.000206	CcSEcCtD
Zalcitabine—Ill-defined disorder—Prednisone—psoriasis	6.24e-05	0.000205	CcSEcCtD
Zalcitabine—Feeling abnormal—Prednisolone—psoriasis	6.23e-05	0.000205	CcSEcCtD
Zalcitabine—Visual impairment—Methotrexate—psoriasis	6.22e-05	0.000205	CcSEcCtD
Zalcitabine—Anaemia—Prednisone—psoriasis	6.22e-05	0.000205	CcSEcCtD
Zalcitabine—Shock—Betamethasone—psoriasis	6.2e-05	0.000204	CcSEcCtD
Zalcitabine—Shock—Dexamethasone—psoriasis	6.2e-05	0.000204	CcSEcCtD
Zalcitabine—Dyspnoea—Triamcinolone—psoriasis	6.2e-05	0.000204	CcSEcCtD
Zalcitabine—Agitation—Prednisone—psoriasis	6.18e-05	0.000204	CcSEcCtD
Zalcitabine—Thrombocytopenia—Dexamethasone—psoriasis	6.17e-05	0.000203	CcSEcCtD
Zalcitabine—Thrombocytopenia—Betamethasone—psoriasis	6.17e-05	0.000203	CcSEcCtD
Zalcitabine—Tachycardia—Dexamethasone—psoriasis	6.15e-05	0.000203	CcSEcCtD
Zalcitabine—Tachycardia—Betamethasone—psoriasis	6.15e-05	0.000203	CcSEcCtD
Zalcitabine—Hypersensitivity—Cyclosporine—psoriasis	6.12e-05	0.000201	CcSEcCtD
Zalcitabine—Dyspepsia—Triamcinolone—psoriasis	6.12e-05	0.000201	CcSEcCtD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—CARM1—psoriasis	6.11e-05	0.00154	CbGpPWpGaD
Zalcitabine—Hyperhidrosis—Dexamethasone—psoriasis	6.1e-05	0.000201	CcSEcCtD
Zalcitabine—Hyperhidrosis—Betamethasone—psoriasis	6.1e-05	0.000201	CcSEcCtD
Zalcitabine—Feeling abnormal—Hydrocortisone—psoriasis	6.08e-05	0.0002	CcSEcCtD
Zalcitabine—Malaise—Prednisone—psoriasis	6.07e-05	0.0002	CcSEcCtD
Zalcitabine—Vertigo—Prednisone—psoriasis	6.04e-05	0.000199	CcSEcCtD
Zalcitabine—Eye disorder—Methotrexate—psoriasis	6.04e-05	0.000199	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Hydrocortisone—psoriasis	6.03e-05	0.000199	CcSEcCtD
Zalcitabine—Syncope—Prednisone—psoriasis	6.03e-05	0.000199	CcSEcCtD
Zalcitabine—DCK—Metabolism—CARM1—psoriasis	6.03e-05	0.00152	CbGpPWpGaD
Zalcitabine—Tinnitus—Methotrexate—psoriasis	6.02e-05	0.000198	CcSEcCtD
Zalcitabine—Anorexia—Betamethasone—psoriasis	6.01e-05	0.000198	CcSEcCtD
Zalcitabine—Anorexia—Dexamethasone—psoriasis	6.01e-05	0.000198	CcSEcCtD
Zalcitabine—Urticaria—Prednisolone—psoriasis	6e-05	0.000198	CcSEcCtD
Zalcitabine—Fatigue—Triamcinolone—psoriasis	5.99e-05	0.000197	CcSEcCtD
Zalcitabine—Hypersensitivity—Mycophenolate mofetil—psoriasis	5.97e-05	0.000196	CcSEcCtD
Zalcitabine—Asthenia—Cyclosporine—psoriasis	5.96e-05	0.000196	CcSEcCtD
Zalcitabine—Pain—Triamcinolone—psoriasis	5.94e-05	0.000196	CcSEcCtD
Zalcitabine—CYP3A43—Metabolism—CARM1—psoriasis	5.93e-05	0.0015	CbGpPWpGaD
Zalcitabine—Loss of consciousness—Prednisone—psoriasis	5.91e-05	0.000195	CcSEcCtD
Zalcitabine—Pruritus—Cyclosporine—psoriasis	5.88e-05	0.000193	CcSEcCtD
Zalcitabine—Urticaria—Hydrocortisone—psoriasis	5.86e-05	0.000193	CcSEcCtD
Zalcitabine—Abdominal pain—Hydrocortisone—psoriasis	5.83e-05	0.000192	CcSEcCtD
Zalcitabine—Body temperature increased—Hydrocortisone—psoriasis	5.83e-05	0.000192	CcSEcCtD
Zalcitabine—Convulsion—Prednisone—psoriasis	5.83e-05	0.000192	CcSEcCtD
Zalcitabine—Asthenia—Mycophenolate mofetil—psoriasis	5.81e-05	0.000191	CcSEcCtD
Zalcitabine—Hypertension—Prednisone—psoriasis	5.81e-05	0.000191	CcSEcCtD
Zalcitabine—Chills—Methotrexate—psoriasis	5.8e-05	0.000191	CcSEcCtD
Zalcitabine—CYP3A7—Metabolism—NDUFA5—psoriasis	5.76e-05	0.00145	CbGpPWpGaD
Zalcitabine—Musculoskeletal discomfort—Dexamethasone—psoriasis	5.74e-05	0.000189	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Betamethasone—psoriasis	5.74e-05	0.000189	CcSEcCtD
Zalcitabine—Pruritus—Mycophenolate mofetil—psoriasis	5.73e-05	0.000189	CcSEcCtD
Zalcitabine—Arthralgia—Prednisone—psoriasis	5.73e-05	0.000189	CcSEcCtD
Zalcitabine—Myalgia—Prednisone—psoriasis	5.73e-05	0.000189	CcSEcCtD
Zalcitabine—Feeling abnormal—Triamcinolone—psoriasis	5.73e-05	0.000188	CcSEcCtD
Zalcitabine—Anxiety—Prednisone—psoriasis	5.71e-05	0.000188	CcSEcCtD
Zalcitabine—Alopecia—Methotrexate—psoriasis	5.71e-05	0.000188	CcSEcCtD
Zalcitabine—Insomnia—Betamethasone—psoriasis	5.7e-05	0.000188	CcSEcCtD
Zalcitabine—Insomnia—Dexamethasone—psoriasis	5.7e-05	0.000188	CcSEcCtD
Zalcitabine—Diarrhoea—Cyclosporine—psoriasis	5.68e-05	0.000187	CcSEcCtD
Zalcitabine—Discomfort—Prednisone—psoriasis	5.66e-05	0.000186	CcSEcCtD
Zalcitabine—Hypersensitivity—Prednisolone—psoriasis	5.57e-05	0.000183	CcSEcCtD
Zalcitabine—Dyspepsia—Betamethasone—psoriasis	5.55e-05	0.000183	CcSEcCtD
Zalcitabine—Dyspepsia—Dexamethasone—psoriasis	5.55e-05	0.000183	CcSEcCtD
Zalcitabine—Diarrhoea—Mycophenolate mofetil—psoriasis	5.54e-05	0.000182	CcSEcCtD
Zalcitabine—Urticaria—Triamcinolone—psoriasis	5.52e-05	0.000182	CcSEcCtD
Zalcitabine—Dysgeusia—Methotrexate—psoriasis	5.51e-05	0.000181	CcSEcCtD
Zalcitabine—Body temperature increased—Triamcinolone—psoriasis	5.49e-05	0.000181	CcSEcCtD
Zalcitabine—Dizziness—Cyclosporine—psoriasis	5.49e-05	0.000181	CcSEcCtD
Zalcitabine—Oedema—Prednisone—psoriasis	5.49e-05	0.000181	CcSEcCtD
Zalcitabine—Decreased appetite—Betamethasone—psoriasis	5.48e-05	0.00018	CcSEcCtD
Zalcitabine—Decreased appetite—Dexamethasone—psoriasis	5.48e-05	0.00018	CcSEcCtD
Zalcitabine—Infection—Prednisone—psoriasis	5.46e-05	0.00018	CcSEcCtD
Zalcitabine—Back pain—Methotrexate—psoriasis	5.44e-05	0.000179	CcSEcCtD
Zalcitabine—Hypersensitivity—Hydrocortisone—psoriasis	5.44e-05	0.000179	CcSEcCtD
Zalcitabine—Fatigue—Dexamethasone—psoriasis	5.44e-05	0.000179	CcSEcCtD
Zalcitabine—Fatigue—Betamethasone—psoriasis	5.44e-05	0.000179	CcSEcCtD
Zalcitabine—Shock—Prednisone—psoriasis	5.4e-05	0.000178	CcSEcCtD
Zalcitabine—Pain—Dexamethasone—psoriasis	5.39e-05	0.000177	CcSEcCtD
Zalcitabine—Pain—Betamethasone—psoriasis	5.39e-05	0.000177	CcSEcCtD
Zalcitabine—Tachycardia—Prednisone—psoriasis	5.36e-05	0.000176	CcSEcCtD
Zalcitabine—Dizziness—Mycophenolate mofetil—psoriasis	5.36e-05	0.000176	CcSEcCtD
Zalcitabine—Skin disorder—Prednisone—psoriasis	5.33e-05	0.000176	CcSEcCtD
Zalcitabine—Hyperhidrosis—Prednisone—psoriasis	5.31e-05	0.000175	CcSEcCtD
Zalcitabine—Vision blurred—Methotrexate—psoriasis	5.3e-05	0.000174	CcSEcCtD
Zalcitabine—Asthenia—Hydrocortisone—psoriasis	5.3e-05	0.000174	CcSEcCtD
Zalcitabine—Vomiting—Cyclosporine—psoriasis	5.28e-05	0.000174	CcSEcCtD
Zalcitabine—Rash—Cyclosporine—psoriasis	5.24e-05	0.000172	CcSEcCtD
Zalcitabine—Anorexia—Prednisone—psoriasis	5.23e-05	0.000172	CcSEcCtD
Zalcitabine—Dermatitis—Cyclosporine—psoriasis	5.23e-05	0.000172	CcSEcCtD
Zalcitabine—Pruritus—Hydrocortisone—psoriasis	5.22e-05	0.000172	CcSEcCtD
Zalcitabine—Ill-defined disorder—Methotrexate—psoriasis	5.22e-05	0.000172	CcSEcCtD
Zalcitabine—Headache—Cyclosporine—psoriasis	5.2e-05	0.000171	CcSEcCtD
Zalcitabine—Anaemia—Methotrexate—psoriasis	5.2e-05	0.000171	CcSEcCtD
Zalcitabine—Feeling abnormal—Betamethasone—psoriasis	5.2e-05	0.000171	CcSEcCtD
Zalcitabine—Feeling abnormal—Dexamethasone—psoriasis	5.2e-05	0.000171	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Dexamethasone—psoriasis	5.16e-05	0.00017	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Betamethasone—psoriasis	5.16e-05	0.00017	CcSEcCtD
Zalcitabine—Vomiting—Mycophenolate mofetil—psoriasis	5.15e-05	0.00017	CcSEcCtD
Zalcitabine—Hypersensitivity—Triamcinolone—psoriasis	5.12e-05	0.000169	CcSEcCtD
Zalcitabine—Rash—Mycophenolate mofetil—psoriasis	5.11e-05	0.000168	CcSEcCtD
Zalcitabine—Dermatitis—Mycophenolate mofetil—psoriasis	5.1e-05	0.000168	CcSEcCtD
Zalcitabine—Headache—Mycophenolate mofetil—psoriasis	5.07e-05	0.000167	CcSEcCtD
Zalcitabine—Malaise—Methotrexate—psoriasis	5.07e-05	0.000167	CcSEcCtD
Zalcitabine—Vertigo—Methotrexate—psoriasis	5.05e-05	0.000166	CcSEcCtD
Zalcitabine—Diarrhoea—Hydrocortisone—psoriasis	5.05e-05	0.000166	CcSEcCtD
Zalcitabine—Leukopenia—Methotrexate—psoriasis	5.03e-05	0.000166	CcSEcCtD
Zalcitabine—Urticaria—Betamethasone—psoriasis	5.01e-05	0.000165	CcSEcCtD
Zalcitabine—Urticaria—Dexamethasone—psoriasis	5.01e-05	0.000165	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Prednisone—psoriasis	5e-05	0.000165	CcSEcCtD
Zalcitabine—Dizziness—Prednisolone—psoriasis	5e-05	0.000164	CcSEcCtD
Zalcitabine—Asthenia—Triamcinolone—psoriasis	4.99e-05	0.000164	CcSEcCtD
Zalcitabine—Body temperature increased—Dexamethasone—psoriasis	4.98e-05	0.000164	CcSEcCtD
Zalcitabine—Abdominal pain—Betamethasone—psoriasis	4.98e-05	0.000164	CcSEcCtD
Zalcitabine—Body temperature increased—Betamethasone—psoriasis	4.98e-05	0.000164	CcSEcCtD
Zalcitabine—Abdominal pain—Dexamethasone—psoriasis	4.98e-05	0.000164	CcSEcCtD
Zalcitabine—Insomnia—Prednisone—psoriasis	4.97e-05	0.000163	CcSEcCtD
Zalcitabine—Pruritus—Triamcinolone—psoriasis	4.92e-05	0.000162	CcSEcCtD
Zalcitabine—Cough—Methotrexate—psoriasis	4.91e-05	0.000162	CcSEcCtD
Zalcitabine—CYP3A7—Metabolism—CYP2S1—psoriasis	4.89e-05	0.00124	CbGpPWpGaD
Zalcitabine—Dizziness—Hydrocortisone—psoriasis	4.88e-05	0.000161	CcSEcCtD
Zalcitabine—Convulsion—Methotrexate—psoriasis	4.87e-05	0.00016	CcSEcCtD
Zalcitabine—Dyspepsia—Prednisone—psoriasis	4.83e-05	0.000159	CcSEcCtD
Zalcitabine—Myalgia—Methotrexate—psoriasis	4.79e-05	0.000158	CcSEcCtD
Zalcitabine—Arthralgia—Methotrexate—psoriasis	4.79e-05	0.000158	CcSEcCtD
Zalcitabine—Decreased appetite—Prednisone—psoriasis	4.77e-05	0.000157	CcSEcCtD
Zalcitabine—Rash—Prednisolone—psoriasis	4.76e-05	0.000157	CcSEcCtD
Zalcitabine—Dermatitis—Prednisolone—psoriasis	4.76e-05	0.000157	CcSEcCtD
Zalcitabine—Fatigue—Prednisone—psoriasis	4.73e-05	0.000156	CcSEcCtD
Zalcitabine—Headache—Prednisolone—psoriasis	4.73e-05	0.000156	CcSEcCtD
Zalcitabine—Discomfort—Methotrexate—psoriasis	4.73e-05	0.000156	CcSEcCtD
Zalcitabine—Vomiting—Hydrocortisone—psoriasis	4.69e-05	0.000154	CcSEcCtD
Zalcitabine—Rash—Hydrocortisone—psoriasis	4.65e-05	0.000153	CcSEcCtD
Zalcitabine—Dermatitis—Hydrocortisone—psoriasis	4.65e-05	0.000153	CcSEcCtD
Zalcitabine—Confusional state—Methotrexate—psoriasis	4.63e-05	0.000152	CcSEcCtD
Zalcitabine—Headache—Hydrocortisone—psoriasis	4.62e-05	0.000152	CcSEcCtD
Zalcitabine—Dizziness—Triamcinolone—psoriasis	4.6e-05	0.000151	CcSEcCtD
Zalcitabine—Infection—Methotrexate—psoriasis	4.56e-05	0.00015	CcSEcCtD
Zalcitabine—Feeling abnormal—Prednisone—psoriasis	4.53e-05	0.000149	CcSEcCtD
Zalcitabine—Asthenia—Betamethasone—psoriasis	4.52e-05	0.000149	CcSEcCtD
Zalcitabine—Asthenia—Dexamethasone—psoriasis	4.52e-05	0.000149	CcSEcCtD
Zalcitabine—Thrombocytopenia—Methotrexate—psoriasis	4.49e-05	0.000148	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Prednisone—psoriasis	4.49e-05	0.000148	CcSEcCtD
Zalcitabine—Pruritus—Dexamethasone—psoriasis	4.46e-05	0.000147	CcSEcCtD
Zalcitabine—Pruritus—Betamethasone—psoriasis	4.46e-05	0.000147	CcSEcCtD
Zalcitabine—Skin disorder—Methotrexate—psoriasis	4.46e-05	0.000147	CcSEcCtD
Zalcitabine—Hyperhidrosis—Methotrexate—psoriasis	4.44e-05	0.000146	CcSEcCtD
Zalcitabine—Vomiting—Triamcinolone—psoriasis	4.42e-05	0.000145	CcSEcCtD
Zalcitabine—Rash—Triamcinolone—psoriasis	4.38e-05	0.000144	CcSEcCtD
Zalcitabine—Dermatitis—Triamcinolone—psoriasis	4.38e-05	0.000144	CcSEcCtD
Zalcitabine—Anorexia—Methotrexate—psoriasis	4.37e-05	0.000144	CcSEcCtD
Zalcitabine—Urticaria—Prednisone—psoriasis	4.36e-05	0.000144	CcSEcCtD
Zalcitabine—Headache—Triamcinolone—psoriasis	4.35e-05	0.000143	CcSEcCtD
Zalcitabine—Abdominal pain—Prednisone—psoriasis	4.34e-05	0.000143	CcSEcCtD
Zalcitabine—Body temperature increased—Prednisone—psoriasis	4.34e-05	0.000143	CcSEcCtD
Zalcitabine—Diarrhoea—Dexamethasone—psoriasis	4.31e-05	0.000142	CcSEcCtD
Zalcitabine—Diarrhoea—Betamethasone—psoriasis	4.31e-05	0.000142	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Methotrexate—psoriasis	4.18e-05	0.000138	CcSEcCtD
Zalcitabine—Dizziness—Dexamethasone—psoriasis	4.17e-05	0.000137	CcSEcCtD
Zalcitabine—Dizziness—Betamethasone—psoriasis	4.17e-05	0.000137	CcSEcCtD
Zalcitabine—CYP3A5—Metabolism—NDUFA5—psoriasis	4.16e-05	0.00105	CbGpPWpGaD
Zalcitabine—Insomnia—Methotrexate—psoriasis	4.15e-05	0.000137	CcSEcCtD
Zalcitabine—Dyspnoea—Methotrexate—psoriasis	4.09e-05	0.000135	CcSEcCtD
Zalcitabine—Somnolence—Methotrexate—psoriasis	4.08e-05	0.000134	CcSEcCtD
Zalcitabine—Hypersensitivity—Prednisone—psoriasis	4.05e-05	0.000133	CcSEcCtD
Zalcitabine—Dyspepsia—Methotrexate—psoriasis	4.04e-05	0.000133	CcSEcCtD
Zalcitabine—Vomiting—Betamethasone—psoriasis	4.01e-05	0.000132	CcSEcCtD
Zalcitabine—Vomiting—Dexamethasone—psoriasis	4.01e-05	0.000132	CcSEcCtD
Zalcitabine—Decreased appetite—Methotrexate—psoriasis	3.99e-05	0.000131	CcSEcCtD
Zalcitabine—Rash—Betamethasone—psoriasis	3.98e-05	0.000131	CcSEcCtD
Zalcitabine—Rash—Dexamethasone—psoriasis	3.98e-05	0.000131	CcSEcCtD
Zalcitabine—Dermatitis—Betamethasone—psoriasis	3.97e-05	0.000131	CcSEcCtD
Zalcitabine—Dermatitis—Dexamethasone—psoriasis	3.97e-05	0.000131	CcSEcCtD
Zalcitabine—Fatigue—Methotrexate—psoriasis	3.96e-05	0.00013	CcSEcCtD
Zalcitabine—Headache—Dexamethasone—psoriasis	3.95e-05	0.00013	CcSEcCtD
Zalcitabine—Headache—Betamethasone—psoriasis	3.95e-05	0.00013	CcSEcCtD
Zalcitabine—Asthenia—Prednisone—psoriasis	3.94e-05	0.00013	CcSEcCtD
Zalcitabine—Pain—Methotrexate—psoriasis	3.92e-05	0.000129	CcSEcCtD
Zalcitabine—Pruritus—Prednisone—psoriasis	3.89e-05	0.000128	CcSEcCtD
Zalcitabine—Feeling abnormal—Methotrexate—psoriasis	3.78e-05	0.000124	CcSEcCtD
Zalcitabine—Diarrhoea—Prednisone—psoriasis	3.76e-05	0.000124	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Methotrexate—psoriasis	3.75e-05	0.000124	CcSEcCtD
Zalcitabine—DCK—Metabolism—CAT—psoriasis	3.71e-05	0.000937	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—CAT—psoriasis	3.65e-05	0.000923	CbGpPWpGaD
Zalcitabine—Urticaria—Methotrexate—psoriasis	3.65e-05	0.00012	CcSEcCtD
Zalcitabine—Dizziness—Prednisone—psoriasis	3.63e-05	0.00012	CcSEcCtD
Zalcitabine—Body temperature increased—Methotrexate—psoriasis	3.63e-05	0.000119	CcSEcCtD
Zalcitabine—Abdominal pain—Methotrexate—psoriasis	3.63e-05	0.000119	CcSEcCtD
Zalcitabine—CYP3A5—Metabolism—CYP2S1—psoriasis	3.54e-05	0.000894	CbGpPWpGaD
Zalcitabine—Vomiting—Prednisone—psoriasis	3.49e-05	0.000115	CcSEcCtD
Zalcitabine—Rash—Prednisone—psoriasis	3.46e-05	0.000114	CcSEcCtD
Zalcitabine—Dermatitis—Prednisone—psoriasis	3.46e-05	0.000114	CcSEcCtD
Zalcitabine—Headache—Prednisone—psoriasis	3.44e-05	0.000113	CcSEcCtD
Zalcitabine—Hypersensitivity—Methotrexate—psoriasis	3.38e-05	0.000111	CcSEcCtD
Zalcitabine—Asthenia—Methotrexate—psoriasis	3.29e-05	0.000108	CcSEcCtD
Zalcitabine—Pruritus—Methotrexate—psoriasis	3.25e-05	0.000107	CcSEcCtD
Zalcitabine—Diarrhoea—Methotrexate—psoriasis	3.14e-05	0.000103	CcSEcCtD
Zalcitabine—Dizziness—Methotrexate—psoriasis	3.03e-05	9.99e-05	CcSEcCtD
Zalcitabine—CYP2D6—Metabolism—NDUFA5—psoriasis	2.96e-05	0.000748	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—NDUFA5—psoriasis	2.93e-05	0.000741	CbGpPWpGaD
Zalcitabine—Vomiting—Methotrexate—psoriasis	2.92e-05	9.6e-05	CcSEcCtD
Zalcitabine—Rash—Methotrexate—psoriasis	2.89e-05	9.52e-05	CcSEcCtD
Zalcitabine—Dermatitis—Methotrexate—psoriasis	2.89e-05	9.52e-05	CcSEcCtD
Zalcitabine—DCK—Metabolism—APOE—psoriasis	2.88e-05	0.000728	CbGpPWpGaD
Zalcitabine—Headache—Methotrexate—psoriasis	2.87e-05	9.46e-05	CcSEcCtD
Zalcitabine—CYP3A43—Metabolism—APOE—psoriasis	2.84e-05	0.000717	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.73e-05	0.000691	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—CYP2S1—psoriasis	2.52e-05	0.000636	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—PPARG—psoriasis	2.51e-05	0.000634	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—CYP2S1—psoriasis	2.49e-05	0.00063	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—PPARG—psoriasis	2.47e-05	0.000624	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—CARM1—psoriasis	2.39e-05	0.000604	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—NDUFA5—psoriasis	1.93e-05	0.000489	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—CARM1—psoriasis	1.73e-05	0.000437	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—CYP2S1—psoriasis	1.64e-05	0.000416	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—CAT—psoriasis	1.47e-05	0.000372	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.31e-05	0.00033	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—CARM1—psoriasis	1.23e-05	0.000311	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—CARM1—psoriasis	1.22e-05	0.000308	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—APOE—psoriasis	1.14e-05	0.000289	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.14e-05	0.000288	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—CAT—psoriasis	1.06e-05	0.000269	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—PPARG—psoriasis	9.95e-06	0.000251	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—APOE—psoriasis	8.26e-06	0.000209	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—CARM1—psoriasis	8.03e-06	0.000203	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—CAT—psoriasis	7.56e-06	0.000191	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—CAT—psoriasis	7.49e-06	0.000189	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—PPARG—psoriasis	7.19e-06	0.000182	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—APOE—psoriasis	5.87e-06	0.000148	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—APOE—psoriasis	5.82e-06	0.000147	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—PPARG—psoriasis	5.11e-06	0.000129	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—PPARG—psoriasis	5.07e-06	0.000128	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—CAT—psoriasis	4.94e-06	0.000125	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—APOE—psoriasis	3.84e-06	9.7e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—PPARG—psoriasis	3.34e-06	8.45e-05	CbGpPWpGaD
